← Browse by Condition
Medical Condition

relapse

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for relapse sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — relapse Clinical Trials

How many clinical trials are currently recruiting for relapse?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for relapse, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for relapse?
relapse research spans Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a relapse clinical trial?
Eligibility criteria for relapse trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
4
Top Sponsors
Postgraduate Institute of Dental Sciences Rohtak 2 trials
Fudan University 1 trial
First Affiliated Hospital of Zhejiang University 1 trial
Université de Sherbrooke 1 trial
Andrew Yee, MD 1 trial

Recruiting Clinical Trials

NCT07604909 Phase 2
Recruiting

A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy

Enrollment
40 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT07105579 Phase 2
Recruiting

Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia

Enrollment
31 pts
Location
China
Sponsor
First Affiliated Hospital of Z...
View Trial →
NCT06356883 Phase 2
Recruiting

Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma

Enrollment
120 pts
Location
Canada
Sponsor
Université de Sherbrooke
View Trial →
NCT06456827
Recruiting

''Comparative Evaluation of Change in Bite Force and Levels of Bone Turnover Markers CTX and BALP in Hyperdivergent and Hypodivergent Cases During Retention Phases-A Prospective Clinical Trial ''

Enrollment
40 pts
Location
India
Sponsor
Postgraduate Institute of Dent...
View Trial →
NCT07622277
Recruiting

Comparative 3-dimensional Superimposition Analysis of Dentition in Horizontal and Vertical Grower During the Retention Phase -A Prospective Clinical Trial''

Enrollment
44 pts
Location
India
Sponsor
Postgraduate Institute of Dent...
View Trial →
NCT04176718 Phase 2
Recruiting

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Enrollment
43 pts
Location
United States
Sponsor
Andrew Yee, MD
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology